Ipsen's rare genetic disorder drug Sohonos and Biogen's ALS drug Qalsody share a common story: in their clinical trials, each was initially flagged for futility, indicating a low likelihood of success. However, subsequent analyses of the full datasets demonstrated meaningful benefits, and they ultimately received regulatory approval.
InflaRx N.V. (IFRX), the company we are profiling today, is also facing a comparable situation with its phase 3 study of Vilobelimab in pyoderma gangrenosum (PG).
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.